Get started
Author

Sanne de Haas

Bevacizumab in Combination With Chemotherapy As First-Line Therapy in Advanced Gastric Cancer: A Biomarker Evaluation From the AVAGAST Randomized Phase III Trial
2012 · Eric Van Cutsem, Sanne de Haas, et al. · Journal of Clinical Oncology · 475
Markers of Response for the Antiangiogenic Agent Bevacizumab
2013 · Diether Lambrechts, Heinz-Josef Lenz, et al. · Journal of Clinical Oncology · 332
Subjective Sleep Disturbance in Patients with Partial Epilepsy: A Questionnaire‐based Study on Prevalence and Impact on Quality of Life
2004 · Al De Weerd, Sanne De Haas, et al. · Epilepsia · 268
PDF
Trastuzumab Emtansine (T-DM1) in Patients with Previously Treated HER2-Overexpressing Metastatic Non–Small Cell Lung Cancer: Efficacy, Safety, and Biomarkers
2018 · Solange Peters, Rolf Stahel, et al. · Clinical Cancer Research · 236
Functional validation of a genetic locus in the VEGFR-1 tyrosine kinase (TK) domain as a predictive marker for bevacizumab
2012 · Bart Claes, Paul Delmar, et al. · ePrints Soton (University of Southampton) · 194
VEGF pathway genetic variants as biomarkers of treatment outcome with bevacizumab: an analysis of data from the AViTA and AVOREN randomised trials
2012 · Diether Lambrechts, Bart Claes, et al. · The Lancet Oncology · 186
89Zr-Bevacizumab PET Visualizes Heterogeneous Tracer Accumulation in Tumor Lesions of Renal Cell Carcinoma Patients and Differential Effects of Antiangiogenic Treatment
2014 · Sjoukje F. Oosting, Adrienne H. Brouwers, et al. · Journal of Nuclear Medicine · 113
PDF
Trastuzumab emtansine with or without pertuzumab versus trastuzumab with taxane for human epidermal growth factor receptor 2–positive advanced breast cancer: Final results from MARIANNE
2019 · Edith A. Perez, Carlos Barrios, et al. · Cancer · 112
PDF
Effect of an NK1/NK2 Receptor Antagonist on Airway Responses and Inflammation to Allergen in Asthma
2006 · Johan D. Boot, Sanne de Haas, et al. · American Journal of Respiratory and Critical Care Medicine · 69
Biomarker Data from the Phase III KATHERINE Study of Adjuvant T-DM1 versus Trastuzumab for Residual Invasive Disease after Neoadjuvant Therapy for HER2-Positive Breast Cancer
2023 · Carsten Denkert, Chiara Lambertini, et al. · Clinical Cancer Research · 55
PDF
Overall survival (OS) in KATE2, a phase II study of programmed death ligand 1 (PD-L1) inhibitor atezolizumab (atezo)+trastuzumab emtansine (T-DM1) vs placebo (pbo)+T-DM1 in previously treated HER2+ advanced breast cancer (BC)
2019 · L.A. Emens, F.J. Esteva, et al. · Annals of Oncology · 55
Genomic correlates of response to adjuvant trastuzumab (H) and pertuzumab (P) in HER2+ breast cancer (BC): Biomarker analysis of the APHINITY trial.
2019 · Ian E. Krop, Joseph Paulson, et al. · Journal of Clinical Oncology · 52
Genetic variability of VEGF pathway genes in six randomized phase III trials assessing the addition of bevacizumab to standard therapy
2014 · Sanne de Haas, Paul Delmar, et al. · Angiogenesis · 51
PDF
Abstract PD3-01: Results from KATE2, a randomized phase 2 study of atezolizumab (atezo)+trastuzumab emtansine (T-DM1) vs placebo (pbo)+T-DM1 in previously treated HER2+ advanced breast cancer (BC)
2019 · LA Emens, F Esteva, et al. · Cancer Research · 47
Abstract LB-63: Relationship between tumor biomarkers (BM) and efficacy in EMILIA, a phase III study of trastuzumab emtansine (T-DM1) in HER2-positive metastatic breast cancer (MBC).
2013 · José Baselga, Sunil Verma, et al. · Cancer Research · 45
Adjuvant Pertuzumab and Trastuzumab in Early Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer in the APHINITY Trial: Third Interim Overall Survival Analysis With Efficacy Update
2024 · Sibylle Loibl, Jacek Jassem, et al. · Journal of Clinical Oncology · 42
De-Escalated Neoadjuvant Trastuzumab-Emtansine With or Without Endocrine Therapy Versus Trastuzumab With Endocrine Therapy in HR+/HER2+ Early Breast Cancer: 5-Year Survival in the WSG-ADAPT-TP Trial
2023 · Nadia Harbeck, Ulrike A. Nitz, et al. · Journal of Clinical Oncology · 39
Biomarker data from KATHERINE: A phase III study of adjuvant trastuzumab emtansine (T-DM1) versus trastuzumab (H) in patients with residual invasive disease after neoadjuvant therapy for HER2-positive breast cancer.
2020 · Carsten Denkert, Chiara Lambertini, et al. · Journal of Clinical Oncology · 32
Efficacy, safety, and biomarker results of trastuzumab emtansine (T-DM1) in patients (pts) with previously treated HER2-overexpressing locally advanced or metastatic non-small cell lung cancer (mNSCLC).
2017 · Tom Stinchcombe, Rolf A. Stahel, et al. · Journal of Clinical Oncology · 31
Genetic markers of bevacizumab-induced hypertension
2014 · Diether Lambrechts, Matthieu Moisse, et al. · Angiogenesis · 31
PDF
An Overview of the CNS-Pharmacodynamic Profiles of Nonselective and Selective GABA Agonists
2012 · Xia Chen, Sanne de Haas, et al. · Advances in Pharmacological Sciences · 30
PDF
803 ORAL Analysis of Blood Plasma Factors in the AVITA Phase III Randomized Study of Bevacizumab (bev) With Gemcitabine-Erlotinib (GE) in Patients (pts) With Metastatic Pancreatic Cancer (mPC)
2011 · E. Van Cutsem, G. Jayson, et al. · European Journal of Cancer · 30
9172 Analysis of biomarkers (BMs) in the AVAiL phase III randomised study of first-line Bevacizumab (Bv) with cisplatin-gemcitabine (CG) in patients (pts) with non-small cell lung cancer (NSCLC)
2009 · N. Leighl, M. Reck, et al. · European Journal of Cancer Supplements · 15
Pseudohallucinations After Zolpidem Intake
2007 · Sanne de Haas, Jasper Dingemanse, et al. · Journal of Clinical Psychopharmacology · 15
89 Zr-bevacizumab PET imaging in metastatic renal cell carcinoma patients before and during antiangiogenic treatment.
2012 · Sjoukje Oosting, Adrienne H. Brouwers, et al. · Journal of Clinical Oncology · 14
Works count: 87
Citation count: 2,624
H-index: 22
I10-index: 27
Year
Topic
Type